Screener
Cytokinetics CYTK Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: Cytokinetics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:30 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338217
| Line item | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|
| Taxes paid related to net share settlement of equity awards | (2,327) | (527) |
| Net cash provided by financing activities | 800,627 | 83,287 |
| Effect of exchange rate changes on cash | (1,078) | (952) |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 132,746 | (18,681) |
| Cash, cash equivalents, and restricted cash, beginning of period | 125,632 | 95,232 |
| Cash, cash equivalents, and restricted cash, end of period | $258,378 | $76,551 |
| Supplemental cash flow disclosures: | ||
| Cash paid for interest | $12,194 | $10,253 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Cytokinetics's net change in cash?
- Cytokinetics (CYTK) reported net change in cash of $125.42M in Q2 2026.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about Cytokinetics's net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude